Skip to main content Skip to section navigation Skip to footer
VolitionRx Ltd
  • Our Technology
    • Nu.Q® Technology Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
      • Our Tests
      • Human Health
      • Nu.Q® NETs Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
      • Nu.Q® Discover Buy our Nu.Q® Discover H3.1 Research Use Only Assay
      • Animal Health
      • Nu.Q® Vet Cancer Test Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
      • Our Service
      • Nu.Q® Discover Nu.Q® Discover gives you access to a range of assays, built on our proprietary Nucleosomics™ platform, for rapid epigenetic profiling in disease model development, preclinical testing and clinical studies.
      • Our Pipeline Development
      • Nu.Q® Cancer We are developing a range of blood-based assays with potential applications beyond cancer detection.
      • Breakthrough Cancer Detection Method We have developed a novel method for liquid biopsy enabling rapid, cost-effective cancer detection in a routine blood test.
  • Human Health
    • Cancer
    • Sepsis
  • Nu.Q® Products
    • Nu.Q® NETs Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
    • Nu.Q® Discover Buy our Nu.Q® Discover H3.1 Research Use Only Assay
    • Nu.Q® Vet Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
  • Resources
    • Press Releases Latest news on Volition and our products.
    • Scientific Resources for educational and research purposes.
    • Events & Webinars Resources for educational and research purposes.
    • Media Toolkit & Downloads Our library for images and educational downloads.
    View all resources
  • About
    • Our Company Volition means to have determination and a purpose.
    • Our Team Get to know our team of experts behind our research and products.
    • Careers We’re always looking for talented individuals to join our mission.
  • Investors
Join Mailing List

Investor Relations

IR Calendar.

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Video Gallery
    • IR Calendar
    • Presentations & Reports
    • Email Alerts
    • Shareholders Letters
  • Company Info
    • Company Profile
    • Executive Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

  • News & Events

  • Overview
  • Press Releases
  • Video Gallery
  • IR Calendar
  • Presentations & Reports
  • Email Alerts
  • Shareholders Letters

First Quarter 2023 Earnings Conference Call

May 11, 2023 8:30 am EDT
Earnings Release HTML PDF
Earnings Webcast Audio
10-Q HTML PDF
XBRL ZIP
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
logo
  • Nu.Q® Technology
  • Nu.Q® NETs
  • Nu.Q® Vets
  • Nu.Q® Discover
  • Nu.Q® Cancer
  • Disease Areas
  • Cancer
  • Sepsis
  • Resources
  • Blog
  • Scientific
  • Investors
  • Veterinary Resources
  • Company
  • About Us
  • Our Expert Team
  • Careers

Our mission is to save lives and improve outcomes for millions of people and animals worldwide.

Looking for Investor Updates and Press Releases?
Click here

  • eIFU Resources
  • Privacy Policy
  • Cookies Policy
  • Disclaimer
  • © 2026 Web Agency London
  • Twitter
  • Facebook
  • Linkedin

The European regional development fund and Wallonia are investing in your future.

http://europe.wallonie.be

  • logo-eu
  • logo-wallonie
Back to top